Current Assets

Cash & Equivalents

Zimmer Biomet Holdings Cash & Equivalents decreased by 28.3% to $424.20M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 69.4%, from $1.38B to $424.20M. Over 5 years (FY 2020 to FY 2025), Cash & Equivalents shows a downward trend with a -5.9% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.

Analysis

StatementBalance Sheet Statement
SectionCurrent Assets
CategoryLiquidity
SignalHigher is better
VolatilityModerate
First reportedQ4 2012
Last reportedQ1 2026May 1, 2026

How to read this metric

Higher levels indicate strong liquidity and financial flexibility; lower levels may signal potential cash flow issues.

Detailed definition

This represents the most liquid assets held by the company, including cash on hand, demand deposits, and short-term inve...

Peer comparison

A universal metric for assessing a company's immediate financial health.

Metric ID: cash_and_equivalents

Historical Data

20 periods
 Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Value$1.04B$919.60M$378.10M$435.80M$386.40M$545.40M$375.70M$330.20M$319.80M$292.10M$415.80M$393.00M$420.10M$569.00M$525.50M$1.38B$556.90M$1.29B$591.90M$424.20M
QoQ Change-11.8%-58.9%+15.3%-11.3%+41.1%-31.1%-12.1%-3.1%-8.7%+42.3%-5.5%+6.9%+35.4%-7.6%+163.5%-59.8%+132.1%-54.2%-28.3%
YoY Change-62.9%-40.7%-0.6%-24.2%-17.2%-46.4%+10.7%+19.0%+31.4%+94.8%+26.4%+252.3%+32.6%+127.2%+12.6%-69.4%
Range$292.10M$1.38B
CAGR-17.2%
Avg YoY Growth+21.6%
Median YoY Growth+11.7%
Current Streak2 quarters decline

Frequently Asked Questions

What is Zimmer Biomet Holdings's cash & equivalents?
Zimmer Biomet Holdings (ZBH) reported cash & equivalents of $424.20M in Q1 2026.
How has Zimmer Biomet Holdings's cash & equivalents changed year-over-year?
Zimmer Biomet Holdings's cash & equivalents decreased by 69.4% year-over-year, from $1.38B to $424.20M.
What is the long-term trend for Zimmer Biomet Holdings's cash & equivalents?
Over 5 years (2020 to 2025), Zimmer Biomet Holdings's cash & equivalents has grown at a -5.9% compound annual growth rate (CAGR), from $802.10M to $591.90M.
What does cash & equivalents mean?
Cash and highly liquid assets that can be converted to cash within 90 days.